ArticleNature2021
Elevated NSD3 histone methylation activity drives squamous cell lung cancer.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.
0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed
8.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 149 citations in OpenAlex.
- NSD Histone Methyltransferases in Solid Tumors: Biological Functions, Oncogenic Mechanisms and Therapeutic Targeting.International journal of molecular sciences · 2026Review
- Histone modifications: mechanisms, metabolic regulation, and therapeutic targeting in cancer.Precision clinical medicine · 2026Review
- Epigenetics in lung cancer precision medicine: from bench to bedside-a narrative review.Translational lung cancer research · 2026Review
- FSTL4 interaction with Gαi proteins activates the Akt-mTOR pathway to drive malignant phenotypes in non-small cell lung cancer.Cell communication and signaling : CCS · 2026Article
- The histone methyltransferase NSD3 oncogene triggers ribosomal DNA transcription, interfering with FOSL2 in cancer.Cell death & disease · 2026Article
- BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Molecular biomedicine · 2026Review
- NSD3 stabilizes nuclear compartmentalization and promotes megabase-scale chromatin interactions.bioRxiv : the preprint server for biology · 2026Article
- Immune-related LncRNA signatures define tumor microenvironment subtypes and predict immunotherapy response in NSCLC.Discover oncology · 2026Article
- Identification and validation of an m1A-score model to predict outcomes and immunomodulation in lung squamous cell carcinoma by integrated analysis of single-cell and bulk RNA sequencing.Discover oncology · 2026Article
- Many faces of mammalian NSD methyltransferases.Cellular & molecular biology letters · 2026Review
- Article
- Article
- Review
- Copy Number Alteration Profiling from Plasma cfDNA WES in Advanced NSCLC.International journal of molecular sciences · 2025Article
- NSD Family-Mediated H3K36 Methylation in Human Cancer: Mechanisms and Therapeutic Opportunities.Biomedicines · 2025Review
- Enhancer Reprogramming Reveals the Tumorigenic Role of PTPRZ1 in Lung Squamous Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Decoding the tumor immune microenvironment in lung squamous cell carcinoma: characteristics, regulatory mechanisms, and future directions in immunotherapy.Translational lung cancer research · 2025Review
- SETD2 suppresses tumorigenesis in a KRASeLife · 2025Article
- Acquisition ofJTO clinical and research reports · 2025Article
- Research status of small molecule inhibitors, probes, and degraders of NSDs: a comprehensive review.Future medicinal chemistry · 2025Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
22 authors at 8 institutions in 4 countries.
Gang Yuan *Department of Biology, Stanford University, Stanford, CA, USA.
Natasha M Flores *Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Simone HausmannDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shane M LofgrenDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vladlena KharchenkoDivision of Biological and Environmental Science and Engineering, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia.
Maria Angulo-IbanezDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Deepanwita SenguptaDepartment of Biology, Stanford University, Stanford, CA, USA.
Xiaoyin LuDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Iwona CzabanDivision of Biological and Environmental Science and Engineering, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia.ORCID http://orcid.org/0000-0002-8038-1573
Dulat AzhibekDivision of Biological and Environmental Science and Engineering, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia.
Silvestre VicentUniversity of Navarra, Center for Applied Medical Research, Pamplona, Spain.
Wolfgang FischleDivision of Biological and Environmental Science and Engineering, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia.
Mariusz JaremkoDivision of Biological and Environmental Science and Engineering, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia.
Bingliang FangDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ignacio I WistubaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Katrin F ChuaDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-3821-4226
Jack A RothDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-8955-1313
John D MinnaHamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Ning-Yi ShaoFaculty of Health Sciences, University of Macau, Macau SAR, China. nshao@um.edu.mo.ORCID http://orcid.org/0000-0003-4231-828X
Łukasz JaremkoDivision of Biological and Environmental Science and Engineering, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia. lukasz.jaremko@kaust.edu.sa.ORCID http://orcid.org/0000-0001-7684-9359
Pawel K MazurDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. pkmazur@mdanderson.org.ORCID http://orcid.org/0000-0002-5820-8344
Or GozaniDepartment of Biology, Stanford University, Stanford, CA, USA. ogozani@stanford.edu.ORCID http://orcid.org/0000-0002-1365-4463
The University of Texas MD Anderson Cancer Center · USKing Abdullah University of Science and Technology · SAStanford University · USVA Palo Alto Health Care System · USSouthwestern Medical Center · USStanford Medicine · USUniversidad de Navarra · ESUniversity of Macau · MO
Funding
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4MUniversity of Texas PDX Development and Trial CenterU54CA224065 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MERIC-BERNSTAM, FUNDA, ROTH, JACK · 2017 to 2022
$7.7MFunction of PHD Domain Proteins in Chromatin RegulationR01GM079641 · NIGMS · STANFORD UNIVERSITY · PI GOZANI, OR P. · 2007 to 2020
$4.5MFunction of Protein Methylation in Chromatin and Signaling RegulationR35GM139569 · NIGMS · STANFORD UNIVERSITY · PI Or P. Gozani · 2021 to 2026
$4.0MRole of the METTL13 Lysine Methyltransferase in Signaling and CancerR01CA236118 · NCI · STANFORD UNIVERSITY · PI GOZANI, OR P., MAZUR, PAWEL K. · 2019 to 2023
$2.4MRole of SETD5 in Chromatin Regulation and TumorigenesisR01CA236949 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MAZUR, PAWEL K. · 2019 to 2023
$1.9MMolecular Mechanisms of Mammalian SIRT6 FunctionR01AG050997 · NIA · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI CHUA, KATRIN F · 2016 to 2020
$1.7MThe SMYD3-ERK5 signaling module in pancreatic cancerR00CA197816 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MAZUR, PAWEL K. · 2017 to 2019
$732kMechanisms of translational output control in pancreatic cancerK99CA255936 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HAUSMANN, SIMONE CHRISTINE · 2021 to 2022
$224kElucidating functions of mammalian SIRT7 deacetylase in aging and diseaseI01BX000286 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI Katrin F. Chua · 2009 to 2026
–BLRD VA I01 BX000286NCI NIH HHS K99 CA255936NCI NIH HHS P50 CA070907NCI NIH HHS R00 CA197816NCI NIH HHS R01 CA236118NCI NIH HHS R01 CA236949NCI NIH HHS U54 CA224065NIA NIH HHS R01 AG050997NIGMS NIH HHS R01 GM079641NIGMS NIH HHS R35 GM139569
Abstract
Amplification of chromosomal region 8p11-12 is a common genetic alteration that has been implicated in the aetiology of lung squamous cell carcinoma (LUSC)
Indexed as
AnimalsBiocatalysisCarcinogenesisCarcinoma, Squamous CellFemaleHistone-Lysine N-MethyltransferaseHistonesHumansLung NeoplasmsMaleMethylationMiceModels, MolecularMutationNuclear ProteinsReceptor, Fibroblast Growth Factor, Type 1FGFR1 protein, humanHistone-Lysine N-MethyltransferaseHistonesNSD3 protein, humanNuclear ProteinsReceptor, Fibroblast Growth Factor, Type 1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.